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Human bocavirus 1 (HBoV1) is associated with respiratory infections worldwide, mainly in children. Similar to other parvovi-
ruses, it is believed that HBoV1 can persist for long periods of time in humans, probably throughmaintaining concatemers of
the virus single-stranded DNA genome in the nuclei of infected cells. Recently, HBoV-1 was detected in high rates in adenoid and
palatine tonsils samples from patients with chronic adenotonsillar diseases, but nothing is known about the virus replication
levels in those tissues. A 3-year prospective hospital-based study was conducted to detect and quantify HBoV1 DNA andmRNAs
in samples of the adenoids (AD), palatine tonsils (PT), nasopharyngeal secretions (NPS), and peripheral blood (PB) from pa-
tients undergoing tonsillectomy for tonsillar hypertrophy or recurrent tonsillitis. HBoV1 was detected in 25.3% of the AD sam-
ples, while the rates of detection in the PT, NPS, and PB samples were 7.2%, 10.5%, and 1.7%, respectively. The viral loads were
higher in AD samples, and 27.3% of the patients with HBoV hadmRNA detectable in this tissue. High viral loads and detectable
mRNA in the ADwere associated with HBoV1 detection in the other sample sites. The adenoids are an important site of HBoV1
replication and persistence in children with tonsillar hypertrophy. The adenoids contain high HBoV1 loads and are frequently
positive for HBoVmRNA, and this is associated with the detection of HBoV1 in secretions.
Human bocavirus (HBoV) is a small nonenveloped single-stranded DNA virus of the family Parvoviridae (1). HBoV is
highly prevalent in different human populations and has been
detected in association with acute respiratory and gastrointestinal
diseases worldwide (2). Four different species of HBoV are cur-
rently known, designated HBoV1, HBoV2, HBoV3, and HBoV4
(3–5). HBoV1 is mainly detected in respiratory secretions, while
HBoV2 to HBoV4 are frequently found in stool samples from
children.
Koch’s postulates have not yet been fulfilled for HBoV and,
therefore, an association of the agent with human diseases has not
been established, which is further hampered by the high frequency
of simultaneous codetection with other respiratory and enteric
viruses (6, 7). However, there has been increasing evidence that
HBoV, especially HBoV1, is a pathogen rather than an innocent
bystander.
Acute infections by HBoV1, evidenced by methods, such as the
detection of high viral loads in respiratory samples, the presence of
HBoV1 mRNA in nasopharyngeal aspirate samples, and the de-
tection of HBoV1-specific IgM and/or viremia, have frequently
been associated with respiratory illness (6, 8–11). In keeping with
this, in vitro HBoV1 infection of polarized primary human airway
epithelia causes remarkable airway epithelial damage, with a dis-
ruption of the tight junction barrier, loss of cilia, and epithelial cell
hypertrophy (12).
In addition to acute infections, recent studies have shown that
HBoV can establish persistence in humans, mainly by maintain-
ing covalently closed circular viral genomic DNA in infected cells
in several sites, such as respiratory and gut epithelia (13–15). It has
been speculated that chronic HBoV infection might lead to ongo-
ing inflammation, which may be subclinical, eventually leading to
damage in chronically infected tissues. In line with this, HBoV1
DNA has been detected in bronchoalveolar lavage fluid samples
and in different tissues from patients with idiopathic lung fibrosis,
either in association with acute exacerbations of interstitial pneu-
monia or as a finding in postmortem investigations (16).
Despite the evidence for HBoV persistence, not all sites that
harbor such persistence are currently known. The adenoids and
palatine tonsils are prominent secondary lymphoepithelial organs
associated with the upper respiratory tract, where inhaled or in-
gested antigens may come in contact with host defense cells (17).
These tissues have been recognized as sites of persistence of vi-
ruses, such as adenovirus and Epstein-Barr virus (18–20). HBoV1
has been detected in high rates in adenotonsillar tissue (21, 22),
but whether HBoV1 can persist in the adenoids and tonsils re-
mains unknown. The present study was done to investigate
HBoV1 persistence and replication in tonsillar tissues and to
check for its possible association with the pathogenesis of tonsillar
hypertrophy.
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MATERIALS AND METHODS
Patients and sample collection. Detection of the HBoV1 genomic DNA
and mRNAs and a determination of viral loads were done in samples of
the adenoids (AD), palatine tonsils (PT), nasopharyngeal secretions
(NPS), and peripheral blood (PB) from patients of the Division of Oto-
rhinolaryngology of the Clinical Hospital of the Ribeirão Preto School of
Medicine, University of São Paulo, from May 2010 to July 2012. The
enrolled patients were divided in two groups: one composed of 180 pa-
tients (93 males) 1 to 18 years of age (median, 5 years) who underwent
surgical removal of the adenoids and tonsils to treat adenotonsillar hyper-
trophy with clinical evidence of obstructive sleep apnea, or who had re-
current adenotonsillitis according to the criteria of Paradise et al. (23), and
a second group with 12 control patients (7 males) 1 to 12 years of age
(median, 3 years) without chronic adenotonsillitis who underwent sur-
gery for cochlear implant placement. An adenoidectomy was not per-
formed in 6 patients; therefore, only 174 adenoid samples were analyzed.
In the control patients, only small biopsy specimens were collected from
both the adenoids and palatine tonsils. The exclusion criteria were the
presence of symptoms of acute respiratory infection or the use of antibi-
otic treatment 1 month prior to surgery. The study was conducted in
accordance with the principles expressed in the Declaration of Helsinki
and was approved by the clinic’s hospital research ethics committee (file
10466/2008). Written informed consent was obtained from all parents
and guardians prior to enrollment. A detailed description of the criteria
for disease classification and the methods for clinical sample processing
were previously published (22).
DNAandRNA extraction. All samples tested in this study were main-
tained in a preservative solution (RNAlater; Invitrogen, Carlsbad, CA,
USA) at 70°C until nucleic acid extraction. DNA from the tonsils was
extracted from 30 mg of tissue sample with the AllPrep DNA minikit
(Qiagen GmbH, Hilden, Germany), while RNA was obtained using the
AllPrep RNA minikit (Qiagen). Total nucleic acids were extracted from
200 l of NPS with the QIAamp MinElute virus spin kit (Qiagen) and
from 1 ml of peripheral blood with the QIAamp RNA and DNA blood
minikits (Qiagen). All procedures were performed according to the man-
ufacturer’s instructions.
Detection and quantification of HBoV1 viral load. HBoV1 was de-
tected by TaqMan real-time PCR, according to a previously published
protocol (22). Briefly, the reactions were assembled in a final volume of 10
l with 50 ng of DNA, 10 mM forward and reverse primers (HBoV-F,
5=-GCACAGCCACGTGACGAA-3= and HBoV-R, 5=-TGGACTCCCTTT
TCTTTTGTAGGA-3=), 5 mM probe (HBoV-P, 5=-FAM-TGAGCTCAG
GGAATATGAAAGACAAGCATCG-TAMRA-3= [FAM, 6-carboxyfluo-
rescein; TAMRA, 6-carboxytetramethylrhodamine]), and 5.0 l of
TaqMan master mix (Applied Biosystems, Foster City, CA, USA), with the
following parameters: 95°C for 10 min, followed by 45 cycles of 95°C for
15 s and 60°C for 1 min. All TaqMan PCR assays were done on the
StepOnePlus thermocycler (Applied Biosystems), and tests for the house-
keeping control genes -actin and RNase P were done in all samples (22).
Applicable measures to prevent contamination of the PCRs were taken,
including sample handling and reaction mix preparation in separate
rooms. In addition, all TaqMan PCR plates included appropriate negative
controls matched to every step of clinical sample processing.
Quantitative PCR (qPCR) for HBoV1 was targeted to the viral nucleo-
protein 1 (NP1) gene according to previously published procedures (24).
Viral quantification was done in comparison with a standard curve pro-
duced using serial decimal dilutions of a plasmid in which a fragment of
the HBoV1 NP1 gene (nucleotides [nt] 2270 to 3280) had been cloned.
HBoV1 qPCR was considered positive when the threshold was reached
before the 40th cycle. The detection limit was 1 copy of HBoV1 plasmid.
All qPCR assays for HBoV1 were performed in triplicate, and the results
were normalized by amplification of the -actin gene, tested in duplicate
in all batches. The viral loads were determined as the number of copies of
HBoV1 DNA per g of tissue or per ml of NPS or blood sample.
Detection of VP1 andNP1mRNAs of HBoV1. HBoV1 VP1 and NP1
mRNAs were detected by real-time reverse transcription-PCR (RT-PCR)
in NPS, peripheral blood, and tonsil samples to ascertain the presence of
active viral replication in the patients. To ensure target-specific amplification
of cDNA without genomic DNA contamination, total RNA extraction prod-
ucts were treated with DNase I (Invitrogen, Carlsbad, CA, USA) for 2 h prior
to PCR and, as a control, all PCRs were carried out in parallel using RNA
extraction products without previous reverse transcription (RT). In addition,
to ensure RNA quality after DNase treatment, all samples with cDNAs and
DNase-treated RNAs were tested by for-actin by qPCR (6). All RT reactions
were performed with 1 mg of RNA, using 10 pmol of oligo(dT) primer, ac-
cording to the manufacturer’s protocol. PCR was carried out with 150 ng of
cDNA and 300 nmol/liter each primer (VP1-F, 5=-CTCACTTTTCAGACAA
ATATGTGGTTACT-3= and VP1-R, 5=-TGTTGTTTCAATGGCCTCTGT
T-3=), 150 nmol/liter probe (VP1-P, 5=-FAM-TTCAGAATGGTCACCTCT-
AMGBNFQ-3=), and 5 l of TaqMan universal PCR master mix (Applied
Biosystems), according to the same cycling parameters used for the detection
of the HBoV1 genomic DNA. The detection of NP1 mRNA was done by the
same protocol used for VP1 mRNA, except for the primers targeting the NP1
gene, mentioned above in the description of the detection of HBoV1 and
quantification of viral loads.
Detection of other respiratory viruses. All samples were tested by
qualitative real-time PCR for human rhinovirus (HRV), human respira-
tory syncytial virus (HRSV), human metapneumovirus (HMPV), influ-
enza A and B (FLU), human parainfluenza (HPIV), human coronaviruses
(HCoV) 229E and OC43, human adenovirus (HAdV), and human en-
terovirus (HEV), according to previously published procedures (22).
Statistical analysis. Comparisons between the patient groups were
done using chi-square and Fisher’s exact tests; comparisons of the viral
loads between two groups were done by Mann-Whitney or unpaired t test
for groups of less than four individuals; comparisons involving three or
more groups were done by one-way analysis of variance with Bonferroni’s
correction as a posttest. All tests were done using GraphPad Prism version
5.00 for Mac (GraphPad Software, San Diego, CA, USA). A P value of
0.05 was chosen for significance.
RESULTS
Frequency of HBoV1DNAdetection. HBoV1 DNA was detected
in at least one sample in 56 (31.1%) patients with chronic tonsillar
disease. The detection rate was higher in samples from the ade-
noids (AD) (25.3%) than in palatine tonsils (PT) (7.2%), naso-
pharyngeal secretions (NPS) (10.5%), and peripheral blood
(1.7%). Of 180 patients with chronic tonsillar diseases, 49 (27.2%)
had HBoV1 DNA detected in tissue fragments from AD and/or
PT. Among the 56 HBoV1-positive patients, HBoV1 DNA was
detected exclusively in AD in 29 (51.8%) patients, while HBoV1
was detected solely in PT tissue in only 5 (8.9%) patients and solely
in NPS tissue in only 7 (12.5%) patients. In 5 (8.9%), 3 (5.3%),
and 7 (12.5%) patients, HBoV1 genomic DNA was simultane-
ously detected in AD, PT, and NS samples, AD and PT samples,
and AD and NS samples, respectively, while in the vast majority of
HBoV1-positive patients, the viral genomic DNA was detected in
only one of the tested sample sites. In 3 (5.3%) patients, HBoV1
DNA was detected in the peripheral blood and simultaneously in
AD samples, and in 2 of those patients, the virus was detected also
in PT and NPS samples.
The detection of HBoV1 DNA in the adenoids was not associ-
ated with particular clinical signs/symptoms, and virus genomic
DNA was detected in similar rates in patients with chronic tonsil-
lar diseases and in controls without chronic or acute respiratory
symptoms (Table 1). Positive associations of HBoV1 detection in
AD samples were noted with the presence of viral coinfections
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(P 0.001), male gender (P 0.03), and younger age (P 0.04)
(Table 1).
The detection of HBoV1 in PT samples was also associated
with younger age (P  0.04), presence of viral coinfections (P 
0.001), and sleep apnea (P  0.04). However, these associations
should be approached with caution, since the number of patients
with HBoV detected in the PT samples was small (Table 2).
HBoV1 genomic DNA was not detected in PT samples from the
control patients (Table 2).
The high rates of HBoV1 genomic DNA detection in AD and
PT samples, both from patients with tonsillar hypertrophy and
controls, as well as the high frequency of viral coinfections are
indicative of a lack of a causative role for respiratory viruses in
chronic tonsillar hypertrophy. In keeping with this, the number of
different virus types codetected with HBoV1 showed no apparent
correlation with the clinical or demographic data of patients with
chronic tonsillar diseases (see Tables S1 and S2 in the supplemen-
tal material). In addition, the HBoV1 detection rates were not
higher in the presence of any specific virus. In order to verify the
replicative status of HBoV1 in the AD and PT and its potential
relevance for chronic disease development, we determined viral
loads and checked for the presence of mRNAs for two key HBoV1
proteins in all tissues obtained in the study.
The viral load of HBoV1 in tonsillar tissue. The median viral
load in AD samples as determined by qPCR for HBoV1 genomic
DNA was 1.32  106 copies of genomic DNA/g of tissue, which
was not significantly different (P 0.38) from the median of 4.1
105 copies/g obtained in the control patients. In PT samples,
HBoV1 was found only in samples from patients with chronic
adenotonsillitis, with a median viral load of 8.4 104 copies/g. In
NPS samples, the median viral load was 2.1  104 copies/ml in
samples from patients with chronic tonsillar disease, while in pe-
ripheral blood samples, it was 1.1 103 copies/ml. Although the
median viral loads were not significantly different between the
four sample sites (Fig. 1A), in most patients, there was a pattern of
increased HBoV1 viral load in AD samples compared to those in
the other sites (Fig. 1B). The median HBoV1 viral loads in AD
samples were significantly higher in patients in whom HBoV1 was
detected in several sites than in those with HBoV1 detected in a
single site (Fig. 1C to E), as shown by analysis of variance with
Bonferroni’s correction as a posttest. Although HBoV1 DNA was
detected in the peripheral blood samples from only 3 patients, all
of them had high viral load in their AD samples (107 copies/g),
and HBoV was simultaneously detected in PT and NPS samples,
reinforcing that loads of HBoV1 in AD tissue are likely associated
with virus detection in other sites, such as PT, NPS, and peripheral
blood.
The HBoV1 genomic loads were higher in AD samples from
patients with higher degrees of adenoidal hypertrophy and with
sleep apnea than in those with lesser airway obstruction and with-
out sleep apnea (Fig. 2A). Such differences in the HBoV1 viral
loads were not apparent in PT or in NPS samples (Fig. 2B and C).
A firm association between the genomic DNA loads of HBoV1 and
more severe AD hypertrophy was hard to establish, considering
the high frequency of codetection of other respiratory viruses by
qPCR (see Tables S1 and S2 in the supplemental material). No
significant differences were noted in HBoV1 viral loads in AD, PT,
or NPS samples when stratified by gender or age.
The presence of other respiratory viruses, which conceivably
might stimulate or restrict the replication of HBoV1, apparently
did not affect HBoV1 viral loads in AD, PT, and NPS samples (Fig.
3). Dual infections of HBoV1 with certain specific respiratory vi-
ruses were not significantly associated with higher HBoV1 viral
loads (Fig. 3D to Fig. 3F).
Productive infection byHBoV1 in tonsillar tissues. The high
rates of HBoV1 genomic DNA detection and high viral loads are
indirect evidence that the adenoids are an important site for
HBoV1 replication. In order to ascertain the presence of HBoV1
replication in the AD, PT, and NPS, we performed an assay to
detect HBoV1 VP1 and NP1 mRNAs by real-time RT-PCR in total
RNA extracts previously treated with DNase I. Of 56 patients with
chronic adenotonsillar disease positive for HBoV1, 12 (21.4%)
were positive for VP1 or NP1 mRNAs. Of those, 9 patients (75%)
had levels of VP1 and NP1 mRNA detectable in AD samples only,
while 3 were positive in AD plus NPS samples and 1 in AD plus PT
plus NPS samples. The frequency of detection of HBoV genomic
DNA in several sites was significantly higher in patients positive
for HBoV mRNA in their AD samples than in those in whom
mRNA was not detected (66.6% versus 21.8%; P  0.02) (see
Table S3 in the supplemental material). All 3 patients with HBoV1
in the peripheral blood had viral mRNA detectable in their AD
TABLE 1 Clinical and demographic data of patients with HBoV1
detected in adenoidsa
Patient demographic
or condition
Hypertrophic patients Control patients
HBoV1
positive
HBoV1
negative
HBoV1
positive
HBoV1
negative
Patients 44 130 4 8
Male genderb 29 (65.9) 62 (47.7) 3 (75.0) 4 (50.0)
Median age (yr)b 4.0 6.0 2.0 4.0
Viral coinfectionb 38 (86.4) 69 (53.1) 2 (50.0) 4 (50.0)
Airway obstruction
0% to 50% 3 (6.8) 14 (10.8)
50% to 75% 17 (38.6) 60 (46.1)
75% to 100% 24 (54.6) 56 (43.1)
Sleep apnea 29 (65.9) 75 (57.7)
Secretory otitis media 5 (11.4) 25 (19.2)
Allergies 12 (27.3) 36 (27.7)
a Data are presented as no. (%), unless otherwise indicated.
b P 0.05.
TABLE 2 Clinical and demographic data of patients with HBoV1
detected in palatine tonsilsa
Patient demographic
or condition
Hypertrophic patients Control patients
HBoV1
positive
HBoV1
negative
HBoV1
positive
HBoV1
negative
Patients 13 167 0 12
Male gender 6 (46.1) 87 (52.1) 0 (0.0) 7 (58.3)
Median age (yr)b 4.0 6.0 3.0
Viral coinfectionb 10 (76.9) 38 (22.7) 0 (0.0) 0 (00.0)
Recurrent tonsillitis 6 (46.1) 84 (50.3)
Tonsillar hypertrophy 11 (84.6) 137 (82.0)
Sleep apneab 11 (84.6) 93 (55.6)
Secretory otitis media 1 (7.7) 29 (17.3)
Allergies 2 (15.4) 46 (27.5)
a Data are presented as no. (%), unless otherwise indicated.
b P 0.05.
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samples. Thus, the adenoids appear to be the main site of HBoV1
replication in patients with chronic tonsillar diseases.
The detection of HBoV1 mRNA significantly correlated with
high viral load (Fig. 4). The median HBoV1 viral load in patients
with detectable viral mRNA in their AD samples was 2.3  107
copies/g, while in AD samples without detectable viral mRNA, the
median viral load was 6.6  105 copies/g (see Table S3 in the
supplemental material). Such a comparison could not be done in
PT samples because mRNA was detected in hypertrophic PT sam-
ples from only one patient who had an HBoV1 viral load of 2.2
109 copies/g (see Table S4 in the supplemental material). It is
noteworthy that the HBoV1 viral load in that one patient was
much higher than the median load of 8.4  104 obtained in PT
samples from patients without detectable mRNA (Fig. 4; see also
Table S4 in the supplemental material).
The presence of HBoV1 VP1 and/or NP1 mRNAs in AD sam-
ples showed no association with age, gender, or any specific clin-
ical features, such as the severity of airway obstruction, presence of
sleep apnea, or secretory otitis media (see Table S3 in the supple-
mental material). Since the detection of HBoV1 mRNA in PT
samples occurred in only one patient (see Table S4 in the supple-
mental material), no conclusions can be made about its relevance.
As observed with HBoV viral loads, the detection of viral coinfec-
tions was not associated with the detection of HBoV mRNA, sug-
gesting that infection by other respiratory viruses does not in-
crease HBoV production in the tonsils (see Table S5 in the
supplemental material).
DISCUSSION
The results of this prospective study of patients with chronic ton-
sillar diseases seen at a reference hospital in southeast Brazil indi-
cate that the adenoids are an important site for the maintenance
and replication activity of HBoV1. Roughly one-third of these
patients, more frequently males around 4 years of age, were posi-
tive for HBoV1 in at least one sample site.
Since its discovery in 2005, HBoV1 has been reported world-
wide in the respiratory secretions of patients with acute respira-
tory infections (2), and recent studies have shown that it can be
detected with a high frequency in palatine tonsils and adenoids
from patients with chronic tonsillar disease (21, 22). Lu et al. (21)
reported a rate of detection of HBoV1 DNA of approximately 32%
in the adenoids of young children (median age, 3.7 years) under-
going adenoidectomy, an observation similar to ours.
Recently, using a reverse genetics model developed by Huang
et al. (25), Deng et al. (12) showed that HBoV1 replicates in well-
differentiated primary cultures of human airway epithelium
(HAE). In addition, those authors reported that HBoV1 infects
commercially available primary cultures of human airway epithe-
FIG 1 HBoV1 viral loads in the different sample sites in patients with hypertrophic tonsillar diseases. (A) Median viral loads (red lines) of HBoV1 per gram of
tissue were higher in adenoid (AD) than in palatine tonsil (PT) samples, and the viral loads per ml were higher in nasopharyngeal secretion (NPS) samples than
in peripheral blood (PB) samples. (B) Median HBoV1 viral loads in the different sample sites of the same patients are connected by lines; (C to E) Median HBoV1
viral loads (red lines) in AD, PT, and NPS samples from patients with HBoV1 detected in these respective sites only, as well as from patients with HBoV1 detected
in more than one site.
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lium (26). Therefore, it is reasonable to speculate that the higher
frequency of HBoV genomic DNA detected in AD (25.1%) than in
PT (7.2%) samples may be related to the fact that in the adenoids,
the epithelium is largely of the pseudostratified ciliated respiratory
kind, while the palatine tonsils are covered by nonkeratinized
stratified squamous epithelia. Moreover, the adenoids are located
in the nasopharynx, where they are exposed to inhaled pathogens,
while the palatine tonsils are located lower in the pharynx, more
distant from inhaled pathogens. Interestingly, the rate of HBoV1
detection in AD tissue was also higher than the rate of detection in
NPS (10.5%), which suggests that the AD are an important site of
HBoV1 replication in the upper airways of young children.
HBoV1 was detected in adenoid samples from control patients
without tonsillar hypertrophy who received cochlear implants at a
frequency similar to that observed in adenoid samples from pa-
tients with tonsillar hypertrophy. In addition, HBoV1 is prone to
the establishment of prolonged shedding (27) and to be detected
along with other pathogenic viruses (6, 10), a finding that was also
confirmed in the present study. Taken together, these findings
indicate that HBoV1 is not the primary etiology of tonsillar hyper-
trophy.
HBoV1 can persist in the nuclei of infected cells, either as single
episomal genomes or as viral DNA concatemers, consistent with
the rolling-hairpin replication of parvoviruses. In fact, several
published results corroborate this hypothesis, including the detec-
tion of viral DNA in the nuclei of infected cells by in situ hybrid-
ization (28) and the characterization of head-to-tail parvoviral
DNA sequences in human samples (13–15). In this regard, the
PCR results obtained in respiratory secretions from children in
Norway indicate that upon acute infection, HBoV1 DNA can per-
sist in detectable levels for several months (9).
It is reasonable to hypothesize that the prolonged persistence
of a DNA virus might trigger the development of chronic inflam-
mation and tonsillar hyperplasia/hypertrophy, facilitating recur-
rent infections and the maintenance of clinical symptoms seen in
the patients in our study. In fact, DNA sensors that are part of the
innate immune system, such as IFI16 and cyclic GMP-AMP syn-
thase (cGAS), might trigger chronic inflammation and damage
stimulated by prolonged HBoV1 infection, similar to that ob-
served with HIV (29) and herpes simplex virus (HSV) (30). In
addition, HBoV1 DNA has been found in the nuclei of lung cancer
cells, suggesting that this virus may contribute to the development
of tissue hyperplasias, as also observed with other DNA viruses,
such as hepatitis B virus (HBV) (28).
Therefore, in order to try to understand the association be-
tween HBoV1 persistence in the adenoids and palatine tonsils and
the development of chronic tonsillar diseases, we determined the
viral load and checked for the presence of two viral mRNAs, VP1
and NP1. To the best of our knowledge, this is the first report on
HBoV1 viral loads and the presence of HBoV1 mRNAs in tissue
samples from chronically ill patients without acute respiratory
symptoms. There was no apparent correlation of the detection of
HBoV mRNA with demographic or clinical features. In fact, in the
present study, a significant proportion of patients had undetect-
able levels of viral mRNA and low viral loads, consistent with viral
DNA persistence.
In patients with acute respiratory illnesses, there is a strong
correlation between high HBoV1 DNA load (107 copies/ml) in
nasopharyngeal secretions and the detection of mRNA as a marker
of viral replication, the absence of viral coinfections, and the pres-
FIG 2 HBoV viral loads in adenoid (A), palatine tonsils (B), and nasopharyn-
geal secretion (C) samples from patients with chronic tonsillar diseases and
different clinical features. Median HBoV viral loads (red lines) were signifi-
cantly higher in patients with more severe adenoidal hypertrophy and with
sleep apnea (A), whereas differences were not present in palatine tonsils (B) or
in nasopharyngeal secretions (C).
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ence of HBoV1 DNAemia (6, 9). In the present study, we also
observed a correlation between higher viral loads and the detec-
tion of HBoV1 mRNAs, both in adenoid and nasopharyngeal se-
cretion samples. These results indicate that for clinical purposes,
the quantification of HBoV1 genomic DNA loads or the detection
of mRNA may be useful for diagnosing acute HBoV1 infections.
In contrast to previous studies of patients with symptoms of acute
respiratory infections, in the present study, the viral loads of
HBoV1 were not higher in patients without viral coinfections.
Higher HBoV1 viral loads but not the presence of HBoV
mRNAs were associated with more severe adenoidal hypertrophy
and sleep apnea. This may mean that there is a higher abundance
of HBoV1 episomal DNA in proliferating cells of hypertrophic
tonsils rather than more intense viral replication. It should also
be kept in mind, however, that the persistence of HBoV1 DNA
may be a contributing factor in helping to maintain chronic
inflammation in already hypertrophic tonsils. In this regard, a
recent study reported an association between HBoV1 and an-
other chronic ailment, otitis media with effusion, suggesting
that persisting viruses can cause lymphoid hyperplasia, leading
to ventilation disorders and impaired immunoreactivity of the
middle ear (31). The current lack of practical assays for markers
FIG 3 HBoV viral loads in tissues (copies of genomic DNA/g) and nasopharyngeal secretion samples (copies of genomic DNA/ml) from patients with
coinfections by other respiratory viruses. (A to C) HBoV1 viral loads in adenoid, palatine tonsils, and nasopharyngeal secretion samples from patients with
HBoV1 as a single agent or simultaneously detected with 1 to 4 other respiratory viruses. (D to F) HBoV1 viral loads in adenoid, palatine tonsils, and
nasopharyngeal secretion samples from patients with HBoV1 as a single agent or in dual infection with other respiratory viruses: human adenovirus (HAdV),
human rhinovirus (HRV), human enterovirus (HEV), human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), influenza virus (FLU),
human parainfluenza virus (HPIV) and human coronavirus (HCoV). Boxes extend from 25th to 75th percentiles, middle whiskers mark median values, and
upper and lower whiskers, respectively, mark the highest and the lowest values.
FIG 4 Quantification of HBoV viral loads (in copies of genomic DNA/g of
tissue or ml, as appropriate) and detection of HBoV VP1 or NP1 mRNAs in
adenoid (AD), palatine tonsils (PT) and nasopharyngeal secretion (NPS) sam-
ples collected from patients with chronic tonsillar hypertrophy. The median
loads (red lines) of HBoV were significantly higher in AD and NPS samples in
patients positive for HBoV mRNA. Since HBoV1 mRNA was detected in a PT
samples from only 1 patient, statistical analysis was not feasible.
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of replication for all respiratory viruses makes it hard to con-
clusively assess how their replicative status may influence in-
fection by the others.
The detection of HBoV1 mRNA and high viral DNA levels in
some palatine tonsils that lack ciliated epithelia suggests that non-
epithelial cells in that tissue can harbor HBoV1 viral replication.
Based on previous evidence (21), such cells are probably lympho-
cytes, but definitive in situ studies are lacking.
In the present study, we documented that the adenoids are a
main site of HBoV1 replication in patients with chronic adeno-
tonsillar diseases. The adenoids of these patients contained the
highest HBoV1 loads and yielded high rates of HBoV1 mRNA,
which was significantly associated with viral DNA detection in
other sites. Additional studies will be required to provide defini-
tive localization of HBoV1 replication and persistence in the ade-
noids and palatine tonsils.
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